Terms: = Prostate cancer AND ATR, Q13535, 545, ENSG00000175054, MEC1, SCKL, SCKL1, FRP1 AND Treatment
95 results:
1. Microwave hyperthermia enhances radiosensitization by decreasing DNA repair efficiency and inducing oxidative stress in PC3 prostatic adenocarcinoma cells.
Wu Y; Liu P; Chen W; Bai S; Chen S; Chen J; Xu X; Xia J; Wu Y; Lai J; Sun C; Lao Z; Wan X; Wu Z
Int J Hyperthermia; 2024; 41(1):2335201. PubMed ID: 38583875
[TBL] [Abstract] [Full Text] [Related]
2. [
Schaefer-Schuler A; Burgard C; Blickle A; Maus S; Petrescu C; Petto S; Bartholomä M; Stemler T; Ezziddin S; Rosar F
Theranostics; 2024; 14(5):1829-1840. PubMed ID: 38505615
[No Abstract] [Full Text] [Related]
3. Harvesting the Power of Green Synthesis: Gold Nanoparticles Tailored for prostate cancer Therapy.
Oliveira M; Sousa A; Sá S; Soares S; Pereira AC; Rocha AC; Pais P; Ferreira D; Almeida C; Luís C; Lima C; Almeida F; Gestoso Á; Duarte MC; Barata P; Martins-Mendes D; Baylina P; Pereira CF; Fernandes R
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396953
[TBL] [Abstract] [Full Text] [Related]
4. DNA Damage Response and Mismatch Repair Gene Defects in Advanced and Metastatic prostate cancer.
Akhoundova D; Francica P; Rottenberg S; Rubin MA
Adv Anat Pathol; 2024 Mar; 31(2):61-69. PubMed ID: 38008971
[TBL] [Abstract] [Full Text] [Related]
5. Mechanisms of PARP Inhibitor Resistance.
O'Connor MJ; Forment JV
Cancer Treat Res; 2023; 186():25-42. PubMed ID: 37978129
[TBL] [Abstract] [Full Text] [Related]
6. Analysis of Quinolinequinone Analogs with Promising Cytotoxic Activity against Breast cancer.
Yilmaz Goler AM; Tarbin Jannuzzi A; Biswas A; Mondal S; Basavanakatti VN; Jayaprakash Venkatesan R; Yıldırım H; Yıldız M; Çelik Onar H; Bayrak N; Jayaprakash V; TuYuN AF
Chem Biodivers; 2023 Sep; 20(9):e202300848. PubMed ID: 37590495
[TBL] [Abstract] [Full Text] [Related]
7. Mechanistic study of dual-function inhibitors targeting topoisomerase II and Rad51-mediated DNA repair pathway against castration-resistant prostate cancer.
Chiang YC; Leu WJ; Chen YC; Ye PC; Hsu YT; Hsiao YC; Hsu JL; Chan SH; Hsu LC; Huang HS; Guh JH
Prostate; 2023 Dec; 83(16):1549-1563. PubMed ID: 37583103
[TBL] [Abstract] [Full Text] [Related]
8. Veratramine Inhibits the Cell Cycle Progression, Migration, and Invasion via ATM/atr Pathway in Androgen-Independent prostate cancer.
Kim HY; Lee SW; Choi SK; Ashim J; Kim W; Beak SM; Park JK; Han JE; Cho GJ; Ryoo ZY; Jeong J; Lee YH; Jeong H; Yu W; Park S
Am J Chin Med; 2023; 51(5):1309-1333. PubMed ID: 37385965
[TBL] [Abstract] [Full Text] [Related]
9. Factors Associated with Long-Term prostate cancer Survival after Palliative Radiotherapy to a Bone Metastasis and Contemporary Palliative Systemic Therapy: A Retrospective, Population-Based Study.
Venugopal B; Shahhat S; Beck J; Hanumanthappa N; Ong AD; Dubey A; Koul R; Bashir B; Chowdhury A; Sivananthan G; Kim JO
Curr Oncol; 2023 Jun; 30(6):5560-5573. PubMed ID: 37366903
[TBL] [Abstract] [Full Text] [Related]
10. Comparing adaptation strategies in MRI-guided online adaptive radiotherapy for prostate cancer: Implications for treatment margins.
Dassen MG; Janssen T; Kusters M; Pos F; Kerkmeijer LGW; van der Heide UA; van der Bijl E
Radiother Oncol; 2023 Sep; 186():109761. PubMed ID: 37348607
[TBL] [Abstract] [Full Text] [Related]
11. Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial.
Abel ML; Takahashi N; Peer C; Redon CE; Nichols S; Vilimas R; Lee MJ; Lee S; Shelat M; Kattappuram R; Sciuto L; Pinkiert D; Graham C; Butcher D; Karim B; Sharma AK; Malin J; Kumar R; Schultz CW; Goyal S; Del Rivero J; Krishnamurthy M; Upadhyay D; Schroeder B; Sissung T; Tyagi M; Kim J; Pommier Y; Aladjem M; Raffeld M; Figg WD; Trepel J; Xi L; Desai P; Thomas A
Clin Cancer Res; 2023 Sep; 29(18):3603-3611. PubMed ID: 37227187
[TBL] [Abstract] [Full Text] [Related]
12. New perspective on DNA response pathway (DDR) in glioblastoma, focus on classic biomarkers and emerging roles of ncRNAs.
Pirlog BO; Ilut S; Pirlog R; Chiroi P; Nutu A; Radutiu DI; Cuc GD; Berindan-Neagoe I; Nabavi SF; Filosa R; Nabavi SM
Expert Rev Mol Med; 2023 May; 25():e18. PubMed ID: 37154101
[TBL] [Abstract] [Full Text] [Related]
13. The ethanol extract of Cyperus exaltatus var. iwasakii exhibits cell cycle dysregulation, ERK1/2/p38 MAPK/AKT phosphorylation, and reduced MMP-9-mediated metastatic capacity in prostate cancer models in vitro and in vivo.
Kim H; Hwang B; Cho S; Kim WJ; Myung SC; Choi YH; Kim WJ; Lee S; Moon SK
Phytomedicine; 2023 Jun; 114():154794. PubMed ID: 37011419
[TBL] [Abstract] [Full Text] [Related]
14. Enzalutamide combination with Arsenic trioxide suppresses the progression of castration-resistant prostate cancer.
Yang X; Zhao J; Wei D; Feng T; Guo P; Li Q; Wang Y; Han Y; Li M; Jiang Y; Luo Y
J Chemother; 2023 Dec; 35(8):760-770. PubMed ID: 37011019
[TBL] [Abstract] [Full Text] [Related]
15. treatment of prostate cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy.
Bidkar AP; Wang S; Bobba KN; Chan E; Bidlingmaier S; Egusa EA; Peter R; Ali U; Meher N; Wadhwa A; Dhrona S; Dasari C; Beckford-Vera D; Su Y; Tang R; Zhang L; He J; Wilson DM; Aggarwal R; VanBrocklin HF; Seo Y; Chou J; Liu B; Flavell RR
Clin Cancer Res; 2023 May; 29(10):1916-1928. PubMed ID: 36917693
[TBL] [Abstract] [Full Text] [Related]
16. Early Plasma Circulating Tumor DNA as a Potential Biomarker of Disease Recurrence in Non-metastatic prostate cancer.
Fei X; Du X; Gong Y; Liu J; Fan L; Wang J; Wang Y; Zhu Y; Pan J; Dong B; Xue W
Cancer Res Treat; 2023 Jul; 55(3):969-977. PubMed ID: 36915250
[TBL] [Abstract] [Full Text] [Related]
17. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for prostate cancer.
Hamdy FC; Donovan JL; Lane JA; Metcalfe C; Davis M; Turner EL; Martin RM; Young GJ; Walsh EI; Bryant RJ; Bollina P; Doble A; Doherty A; Gillatt D; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Paul A; Paez E; Powell P; Rosario DJ; Rowe E; Mason M; Catto JWF; Peters TJ; Oxley J; Williams NJ; Staffurth J; Neal DE;
N Engl J Med; 2023 Apr; 388(17):1547-1558. PubMed ID: 36912538
[TBL] [Abstract] [Full Text] [Related]
18. LncRNA weighted gene co-expression network analysis reveals novel biomarkers related to prostate cancer metastasis.
Liu M; Chen MY; Huang JM; Liu Q; Wang L; Liu R; Yang N; Huang WH; Zhang W
BMC Med Genomics; 2022 Dec; 15(1):256. PubMed ID: 36514044
[TBL] [Abstract] [Full Text] [Related]
19. Ataxia-telangiectasia mutated and ataxia telangiectasia and Rad3-related kinases as therapeutic targets and stratification indicators for prostate cancer.
Gulliver C; Hoffmann R; Baillie GS
Int J Biochem Cell Biol; 2022 Jun; 147():106230. PubMed ID: 35609768
[TBL] [Abstract] [Full Text] [Related]
20. Olaparib for Chinese metastatic castration-resistant prostate cancer: A real-world study of efficacy and gene predictive analysis.
Dong B; Yang B; Chen W; Du X; Fan L; Yao X; Xue W
Med Oncol; 2022 May; 39(5):96. PubMed ID: 35599270
[TBL] [Abstract] [Full Text] [Related]
[Next]
